EQS-News

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment - Seite 2

• Time & Date: March 20, 2024, from 05:00 pm to 08:00 pm (CET)
• Location: bUM Berlin, Germany

• Online Participation: https://www.eventbrite.com/e/hallo-doc-darmkrebs-neue-behandlungsmethoden-und-therapie ansatze-tickets-852062952227
• Phone number for ticket reservations: [phone]

Mainz Biomed is at the forefront of developing market-ready, molecular-genetic diagnostic solutions for life-threatening conditions. Its flagship product, ColoAlert, offers an accurate, non-invasive, and easy-to-use at-home screening test for colorectal cancer, marking a significant advancement in early detection and prevention strategies.

Guido Baechler, Chief Executive Officer of Mainz Biomed, commented, "As we witness a disturbing trend over the past two decades – a rise in colorectal cancer cases among younger populations - it's imperative to focus on innovative solutions and holistic approaches to combat this disease. The HALLO DOC! event represents our commitment to advancing the dialogue on prevention, early detection, and treatment, featuring insights from some of the most esteemed professionals in the field."

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About ColoAlert

ColoAlert, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.